Literature DB >> 20125128

Peripheral and splanchnic indole and oxindole levels in cirrhotic patients: a study on the pathophysiology of hepatic encephalopathy.

Oliviero Riggio1, Guido Mannaioni, Lorenzo Ridola, Stefania Angeloni, Manuela Merli, Vincenzo Carlà, Filippo Maria Salvatori, Flavio Moroni.   

Abstract

OBJECTIVES: Intestinal bacteria metabolize tryptophan into indole, which is then further metabolized into oxindole, a sedative compound putatively involved in the pathophysiology of hepatic encephalopathy (HE). The aim of this study was to measure indole and oxindole levels in patients with cirrhosis with or without HE and to establish whether an intestinal production and a hepatic metabolism of these substances exist.
METHODS: We studied 10 healthy subjects (controls) and 51 cirrhotic patients: 17 without HE, 14 with a minimal HE, 8 with overt HE, and 12 who had undergone a transjugular intrahepatic portosystemic shunt (TIPS) procedure. In the last group, blood was collected from the artery, and the portal and hepatic veins during TIPS construction and from the peripheral veins before, immediately after, and at weekly intervals during the first month after TIPS.
RESULTS: Plasma indole levels were significantly higher in patients with overt HE. Oxindole levels were higher in cirrhotics than in controls. Indole and ammonia were significantly correlated (r=0.66). Peripheral and splanchnic determinations showed that indole was produced in the intestine and cleared by the liver, similar to ammonia. TIPS implantation increased both indole and ammonia levels. After TIPS, the psychometric performance worsened in 4 of the 12 patients. The increase in indole plasma concentrations in these four patients was higher than in those who remained stable after undergoing TIPS.
CONCLUSIONS: Indole correlates with HE and has a significant intestinal production and hepatic extraction; its level increases after TIPS and is related to psychometric performance. These data suggest that indole may be involved in the pathophysiology of HE.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20125128     DOI: 10.1038/ajg.2009.738

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  17 in total

1.  Current concepts in the pathophysiology and management of hepatic encephalopathy.

Authors:  R Todd Frederick
Journal:  Gastroenterol Hepatol (N Y)       Date:  2011-04

2.  Colonic mucosal microbiome differs from stool microbiome in cirrhosis and hepatic encephalopathy and is linked to cognition and inflammation.

Authors:  Jasmohan S Bajaj; Phillip B Hylemon; Jason M Ridlon; Douglas M Heuman; Kalyani Daita; Melanie B White; Pamela Monteith; Nicole A Noble; Masoumeh Sikaroodi; Patrick M Gillevet
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2012-07-19       Impact factor: 4.052

3.  Molecular Adsorbents Recirculating System dialysis in children with cholestatic pruritus.

Authors:  Betti Schaefer; Franz Schaefer; Dieter Wittmer; Guido Engelmann; Daniel Wenning; Claus Peter Schmitt
Journal:  Pediatr Nephrol       Date:  2011-11-15       Impact factor: 3.714

Review 4.  Promises of microbiome-based therapies.

Authors:  Jasmohan S Bajaj; Siew C Ng; Bernd Schnabl
Journal:  J Hepatol       Date:  2022-06       Impact factor: 30.083

Review 5.  Antibiotics for the treatment of hepatic encephalopathy.

Authors:  Kavish R Patidar; Jasmohan S Bajaj
Journal:  Metab Brain Dis       Date:  2013-02-08       Impact factor: 3.584

6.  Modulation of the fecal bile acid profile by gut microbiota in cirrhosis.

Authors:  Genta Kakiyama; William M Pandak; Patrick M Gillevet; Phillip B Hylemon; Douglas M Heuman; Kalyani Daita; Hajime Takei; Akina Muto; Hiroshi Nittono; Jason M Ridlon; Melanie B White; Nicole A Noble; Pamela Monteith; Michael Fuchs; Leroy R Thacker; Masoumeh Sikaroodi; Jasmohan S Bajaj
Journal:  J Hepatol       Date:  2013-01-16       Impact factor: 25.083

7.  Rifaximin therapy and hepatic encephalopathy: Pros and cons.

Authors:  Angelo Zullo; Cesare Hassan; Lorenzo Ridola; Roberto Lorenzetti; Salvatore Ma Campo; Oliviero Riggio
Journal:  World J Gastrointest Pharmacol Ther       Date:  2012-08-06

8.  Clinical manifestations of portal hypertension.

Authors:  Said A Al-Busafi; Julia McNabb-Baltar; Amanda Farag; Nir Hilzenrat
Journal:  Int J Hepatol       Date:  2012-09-17

9.  Hyperammonemia Is Associated with Increasing Severity of Both Liver Cirrhosis and Hepatic Encephalopathy.

Authors:  Abidullah Khan; Maimoona Ayub; Wazir Mohammad Khan
Journal:  Int J Hepatol       Date:  2016-10-25

Review 10.  Hepatic encephalopathy.

Authors:  Wissam Bleibel; Abdullah M S Al-Osaimi
Journal:  Saudi J Gastroenterol       Date:  2012 Sep-Oct       Impact factor: 2.485

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.